Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Institute of Research for Development, France | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
This study aims at estimating the prevalence of chronic hepatitis B virus (HBV) infection in rural Senegal (area of Niakhar) and at evaluating the associated burden in terms of both health-related and socio-economic consequences.
The prevalence of chronic HBV infection in Senegal is among the highest worldwide (10% to 17%) but available prevalence estimates relie on studies conducted in specific subgroups (such as military, pregnant women or blood donors).
The prevalence of HBV chronic infection remains undocumented in the general population of Senegal, and its health-related and socio-economic consequences need to be estimated.
This research is based on a cross-sectional survey conducted in the general population with collection of biological, socio-behavioral and economic data at two levels (at the participants' home and in healthcare centers) in the area of Niakhar (located at 135 kms at the East of Dakar).
The research includes three phases as follows:
(i) Preliminary phase: information and communication about the research within the community, training of stakeholders and pilot survey
(ii) Collection of data in the general population
(iii) Communication of results on HBV status to participants and collection of additional data among HBV chronic individuals
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| HBV testing with dried blood spots (DBS) technique | Diagnostic Test | Survey participants will be tested at home for chronic HBV infection using the DBS technique (collection of drops of whole blood dried onto filter paper). |
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence of chronic HBV infection | HBs Ag positivity with a positive anti-HBc antibody and a negative anti-HBs antibody | At baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence of chronic HBV infection in age classes '0-15 years; 15-35 years, more than 35 years), and in women of childbearing age | HBs Ag positivity | At baseline |
| HBV vaccine coverage (in children born after 2004, year of the introduction of the vaccine in the national program) |
Not provided
Inclusion Criteria:
(i) Living in a household of the research zone (individuals living within participating households for at least 6 months, even non permanently: seasonal workers or individuals studying outside the Niakhar zone)
(ii) Being aged of at least 6 months
(iii) Giving informed consent to participate in the research
Exclusion Criteria:
(i) Being an adult unable to sign informed consent
(ii) Being a child whose parents or legal guardian is not present in the household at the time of the survey
Not provided
Not provided
Not provided
The study population will include all individuals who live (even non-permanently) in the sampled households of the Niakhar area for at least 6 months, who are aged of at least 6 months, and who sign informed consent to participate in the survey.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sylvie BOYER, Dr | Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| At home | Niakhar | Fatick | Senegal |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37143029 | Derived | Djaogol T, Perieres L, Marcellin F, Diouf A, Carrieri MP, Diallo A, Boyer S; ANRS 12356 AmBASS Study Group. Hepatitis B prevention and treatment needs in women in Senegal (ANRS 12356 AmBASS survey). BMC Public Health. 2023 May 5;23(1):825. doi: 10.1186/s12889-023-15710-y. | |
| 31320358 | Derived | Coste M, De Seze M, Diallo A, Carrieri MP, Marcellin F, Boyer S; ANRS 12356 AmBASS Study Group. Burden and impacts of chronic hepatitis B infection in rural Senegal: study protocol of a cross-sectional survey in the area of Niakhar (AmBASS ANRS 12356). BMJ Open. 2019 Jul 17;9(7):e030211. doi: 10.1136/bmjopen-2019-030211. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D019694 | Hepatitis B, Chronic |
| ID | Term |
|---|---|
| D006509 | Hepatitis B |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
HBs Ag negativity with a negative anti-HBc antibody and positive anti-HBs antibody |
| At baseline |
| HBV vaccine efficacy (in children born after 2004, year of the introduction of the vaccine in the national program) | Titration of anti-HBs antibody > 10 UI/l among vaccinated participants | At baseline |
| Mortality associated with chronic HBV infection in the Niakhar area | Rate of deaths in the area | 6 months |
| Morbidity associated with chronic HBV infection in the Niakhar area | Rate of HBV-related hospitalizations/healthcare use in the area | 6 months |
| Quality of life and living conditions of HBV-infected individuals and of their households | Comparison of quality of life scores and socio-economic characteristics between HBV-concerned and HBV not-concerned households | 6 months |
| HBV treatment needs in the Niakhar area and in the country | Number of HBV-chronic individuals eligible to HBV treatment (according to WHO criteria) in the area, extrapolation to the needs in other areas of Senegal | At baseline |
| Number of quality-adjusted life years(QALYs) lost in the absence of HBV treatment | Use of Markov simulation models | 6 months |
| Number of QALYs gained with different scenario of access to HBV treatment | Use of Markov simulation models | 6 months |
| Total cost | Use of Markov simulation models (with different scenarii of change in access to HBV treatment and amount of the financial contributions of populations, government and international programs) | 6 months |
| D018347 |
| Hepadnaviridae Infections |
| D004266 | DNA Virus Infections |
| D014777 | Virus Diseases |
| D006525 | Hepatitis, Viral, Human |
| D006521 | Hepatitis, Chronic |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |